Dendreon Corporation DNDN- Dendreon Corporation (Dendreon) is a biotechnology company focused on the discovery, development and commercialization of therapeutics that may improve cancer treatment options for patients. The Company's product portfolio includes active cellular immunotherapy and small molecule product candidates to treat a range of cancers. Its advanced product candidate is Provenge (sipuleucel-T), an active cellular immunotherapy that has completed three Phase III trials for the treatment of metastatic, castrate-resistant, (also known as androgen-independent or hormone-refractory) prostate cancer. Competitors- Agenus Inc (AGEN), Celldex Therapeutics (CLDX), Tengion (TNGN)
Infospace Inc. INSP- InfoSpace, Inc. (InfoSpace) develops search tools and technologies that assist consumers with finding content and information on the Internet. The Company offers search services that enable Internet users to locate and view content, information, merchants, individuals, and products online. InfoSpace offers search services, through its own Websites, such as Dogpile.com, WebCrawler.com, MetaCrawler.com, and WebFetch.com, as well as through the Websites of distribution partners. Competitors- Google Inc (GOOG), Yahoo! Inc (YHOO), Baidu.com (BIDU)
Molycorp Inc. MCP- Molycorp, Inc. is the only REO producer in the Western Hemisphere and currently produces more than 3,000 metric tons of commercial rare earth materials per year. In addition to its rare earth mine and processing facility at Mountain Pass, California, Molycorp also owns a controlling interest in the Estonia-based Molycorp Silmet AS, which has a production capacity of 3,000 metric tons of rare earth products and 700 metric tons of rare metal products annually and is one of the largest rare metal and rare earth metal producers in Europe. Competitors- Avalon Rare Metals Inc (AVL), 3M Company (MMM), PolyMet Mining Corp (PLM)
SIRIUS XM Radio Inc. SIRI- Sirius XM Radio is set to report their earnings for the first quarter on May 3rd, Tuesday. Analysts are expecting around 220,000 subscriber additions, revenue of around 725 million, and earnings of .01 cent per share. Based on EBITDA guidance of 715 million from the company, we would expect around 150 million for Q1, based on how past years have broken down total year EBITDA numbers. Competitors- Westwood One Inc. (WWON), Cumulus Media Inc (CMLS), Entercom Communications Corp. (ETM)
Vical Inc. VICL- Vical Inc. is expected to gain for benefiting cancer treatment as well, “Allovectin-7, which is a treatment for melanoma, could provide good news from the phase 3 trials”. Vical Incorporated researches and develops biopharmaceutical products based on its deoxyribonucleic acid (DNA) delivery technologies for the prevention and treatment of serious or life-threatening diseases. The Company has five active independent clinical and preclinical development programs in the areas of infectious disease and cancer, including a fully enrolled Phase III clinical trial using the Company's Allovectin-7 immunotherapeutic in patients with metastatic melanoma; a fully enrolled Phase II clinical trial using TransVax, its cytomegalovirus (CMV), therapeutic DNA vaccine; completed Phase I clinical trials using its Hemagglutinin Type 5 and Neuraminidase Type 1 pandemic influenza DNA vaccine formulated with its Vaxfectin adjuvant; a preclinical program using its H1N1 pandemic influenza DNA vaccine formulated with its Vaxfectin adjuvant, and a preclinical program using its CyMVectin prophylactic vaccine formulated with its Vaxfectin adjuvant. Competitors- Sanofi-Aventis SA (SNY), Merck & Co. (MRK), Novartis AG (NVS)
SUBSCRIBE to CEOWORLD Magazine Digital & SAVE UP TO 80% OFF. Reaching more than 85,000 Chief Executive Officers and decision making executives who serve on the boards of leading companies. SUBSCRIBE NOW!!!
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
